Ardelyx (NASDAQ: ARDX) reported Q3 EPS of ($0.70), $0.22 worse than the analyst estimate of ($0.48).

Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015 Results of a pharmacodynamic study expected in January 2016 for RDX022, a novel potassium binder for the treatment of hyperkalemia

For earnings history and earnings-related data on Ardelyx (ARDX) click here.